Fate Therapeutics (FATE) Receivables - Net (2015 - 2026)

Fate Therapeutics has reported Receivables - Net for 10 years, with the latest figure at $704000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 70.74% year-over-year to $704000.0; the trailing twelve-month figure through Mar 2026 stood at $704000.0 (down 70.74% YoY), and the FY2025 full-year result was $916000.0, down 74.12% from the prior year.
• Receivables - Net for Q1 2026 stood at $704000.0, down from $916000.0 in the prior quarter.
• The five-year high for Receivables - Net was $38.5 million in Q4 2022, with the low at $682000.0 in Q3 2025.
• Historically, Receivables - Net has averaged $6.5 million across 5 years, with a median of $2.4 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 343.52% — and 2023, when it plunged 95.25%.
• Fate Therapeutics' Receivables - Net stood at $38.5 million in 2022, then sank by 95.25% to $1.8 million in 2023, then surged by 93.81% to $3.5 million in 2024, then slumped by 74.12% to $916000.0 in 2025, then fell by 23.14% to $704000.0 in 2026.
• The last three Receivables - Net figures came in at $704000.0 (Q1 2026), $916000.0 (Q4 2025), and $682000.0 (Q3 2025), per Business Quant data.